mushrooms


Silo Wellness Announces Successful Launch of 2022 Psilocybin Retreat Schedule and other Corporate Updates

February 23rd, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading global psychedelics company, today announces several corporate updates. On February 4, 2022, the Company completed its first Jamaican psilocybin retreat of 2022 entitled “Renew Your Purpose” (see press release of December […]

Psyched Wellness Successfully Completes Its Largest Extraction and Shipment of AME-1 to Asia

July 24th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – July 22, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company has completed its largest extraction of AME-1 to date, and has successfully shipped […]

Optimi Health Finalizes Planned Build-Out of Mushroom Production and Research Facility

April 27th, 2021 - Ryan Allway

VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to offer an activity update at its 20,000 sq. ft. production and research facility in Princeton, British Columbia. […]

Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

April 27th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – April 27, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (“Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company and its Clinical Research Organization partner, KGK Science, has commenced the next preclinical trial study with […]

There’s no Magic Answer to the Question, “Can I Patent Magic Mushrooms?”

February 24th, 2021 - Ryan Allway

“Patent pending” is a phrase you are likely familiar with. You have seen it stamped on the side of some doodad at the mall or heard it on the TV show that you are binge watching, and you think to yourself, “Wow, I wish I could invent something that everyone thinks is really cool”. Most […]

Combining Traditional Therapies with Psychedelics: SiloPharma Targeting CNS and Neurological Disorders

February 4th, 2021 - Ryan Allway

“Psychedelics” is a buzz word on Wall Street, but much like legal cannabis or bitcoin and blockchain a decade ago, it remains greatly misunderstood as the market emerges. There was a time when psychedelics were only perceived as part of the illicit drug culture. That stigma is disappearing. Loaded with promise, the burgeoning market includes […]

MagicMed: Bringing the Drug Candidate Library Model to Psychedelics

January 20th, 2021 - Ash Stringer

The psychedelics market is often described as “emerging”, “burgeoning”, and other similar words, and while certainly true to a large extent, investors shouldn’t think for a moment this is all new. It’s far from it. There are scores of clinical and preclinical data to leverage, most collected before the Controlled Substance Act was enacted in […]

Tryp Debuts on the Canadian Securities Exchange

December 22nd, 2020 - Ryan Allway

  Tryp Therapeutics Inc. (CSE: TRYP) began trading on the Canadian Securities Exchange (CSE) on December 18, 2020 under the ticker symbol “TRYP”. “Trading on the CSE is a significant milestone in Tryp’s mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicine,” said CEO James Kuo, MD. “All of the […]

Pure Extracts Unveils Plans for Functional Mushrooms

November 30th, 2020 - Ryan Allway

  There are more than 2,000 species of edible fungi and at least 15 have functional benefits that support overall health. Like other superfoods, functional mushrooms have antioxidant properties that support the immune system, dietary fiber to aid in healthy digestion and numerous other benefits to everything from mental clarity to skin health. At the […]

How the Psybrary™ Could Revolutionize Psychedelic Drug Discovery

September 28th, 2020 - Ryan Allway

The psychedelic drug market is projected to grow at a compound annual growth rate of 16.3% over the next eight years to reach $6.85 billion by 2026, according to Data Bridge Market Research. With the potential to treat a wide range of mental health disorders, several organizations are already conducting clinical trials in the space. […]

Cybin Corp.: A Psychedelics Pioneer Led by a Biotech Veteran

September 22nd, 2020 - Ryan Allway

Cybin has become one of the most popular psychedelic companies over the past year. With a unique approach to the market and an experienced management team, the company aims to bring a breakthrough psychedelic therapy to market for those suffering from Major Depressive Disorder and other mental health conditions—and build value for shareholders in the […]

Cybin Corp.: A Diversified Play on Psychedelic Therapeutics

August 26th, 2020 - Ryan Allway

  More than 700 million people around the world suffer from a mental illness, addiction or eating disorder, according to the World Health Organization, which costs the global economy $2.5 trillion each year in direct and indirect costs. Despite these significant costs, large pharmaceutical companies have stopped searching for the next Prozac. Psychedelics, including psilocybin, […]

What Are Functional Mushrooms?

August 17th, 2020 - Ryan Allway

  Most people think of white buttons at the grocery store when they think of mushrooms, but in reality, there are hundreds of different kinds of mushrooms. Functional mushrooms—like functional foods and beverages—are mushroom varieties that provide a health benefit, ranging from run-of-the-mill vitamins and minerals to important nutrients, including selenium, potassium, riboflavin, niacin, proteins, […]

Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer

April 6th, 2020 - Ryan Allway

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has […]

Psychedelics: Investing in the Perfect BrainStorm

April 6th, 2020 - Ryan Allway

Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space.  In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: […]

5 Ways to Participate in the Psychedelics Boom

March 27th, 2020 - Ryan Allway

The psychedelics industry is quickly becoming the next frontier market for investors as the cannabis industry matures. Through a combination of cutting-edge research and decriminalization, investors are hoping that the industry moves in the same direction as medical cannabis over the coming years. Let’s take a look at five public companies in the space and […]

The Yield Growth Corp. Keeps Growing Like a Weed…or a Mushroom

November 26th, 2019 - Ash Stringer

While some companies are scratching their heads about what to make of the brutal treatment cannabis stocks have felt this year, The Yield Growth Corp. (CSE: BOSS)(OTCQB: BOSQF) seems undaunted, expanding its cannabis business while rapidly emerging as a leading public company in the mushroom space. Click here to receive an investor deck and corporate […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading